Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 14/20 | 0.57 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112676 | 0.94 | GPR84 (0.65) | GPR84APAF1ALDH1A1TYMPELANE | |
| SCHEMBL23133077 | 0.80 | GPR84 (0.41) | GPR84CYP1A2TYMPCYP2C9CYP2C19 | |
| SCHEMBL12219726 | 0.78 | GPR84 (0.90) | GPR84TYMP | |
| SCHEMBL3261738 | 0.73 | GPR84 (1.00) | GPR84TYMP | |
| SCHEMBL30361812 | 0.72 | GPR84 (1.00) | GPR84TYMP | |
| SCHEMBL17375502 | 0.72 | GPR84 (1.00) | GPR84TYMP | |
| SCHEMBL9005802 | 0.68 | GPR84 (0.61) | GPR84ALDH1A1 | |
| SCHEMBL1441267 | 0.66 | GPR84 (0.57) | GPR84TYMPELANE | |
| SCHEMBL9005708 | 0.65 | DAO (0.66) | GPR84CYP2C19 | |
| SCHEMBL8709983 | 0.65 | GPR84 (0.77) | GPR84TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000773-A1 | NOVEL HEADGROUP LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | LNPK, PEBP1, PLTP | GPR84 3400/4885APAF1 1304/4885ALDH1A1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.